 |
市場調查報告書
商品編碼
1890919
血脂異常症治療市場：依適應症、藥物類別、給藥途徑、年齡層、性別、通路和地區分類Lipid Disorder Treatment Market, By Indication, By Drug Class, By Route of Administration, By Age Group, By Gender, By Distribution Channel, By Geography |
||||||
預計到 2025 年，血脂異常症治療市場價值將達到 301.4 億美元，到 2032 年將達到 513.2 億美元，2025 年至 2032 年的複合年成長率為 7.9%。
| 報告內容 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2024 | 2025年市場規模： | 301.4億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2025年至2032年 |
| 預測期（2025-2032年）複合年成長率： | 7.90% | 2032 年的預測值： | 513.2億美元 |
全球血脂異常症治療市場是醫藥和醫療保健產業的重要組成部分，旨在應對全球日益普遍的血脂異常症及其相關心血管併發症。血脂異常的特徵是血脂異常症，已成為影響全球數百萬人的重大公共衛生問題。
高膽固醇症、高三酸甘油脂血症和混合型血脂異常等疾病是心血管疾病的主要危險因素，而心血管疾病是全球主要的死亡原因之一。治療方法包括多種治療方法，例如他汀類藥物、貝特類藥物、膽汁酸螯合劑、PCSK9抑制劑以及針對不同脂質代謝途徑的新興創新治療方法。
推動這一市場成長的因素包括：人們對心血管健康的日益關注、肥胖和糖尿病盛行率的上升、久坐的生活方式以及已開發國家和開發中國家人口的老化。此外，持續的研發活動不斷推出療效和安全性更高的創新療法，促進了市場擴張，並為醫療專業人員提供了多種治療選擇，以有效控制血脂異常症。
市場動態
全球血脂異常症治療市場的主要驅動力是心血管和代謝疾病盛行率的不斷上升，其中肥胖、糖尿病和高血壓是全球血脂異常症的主要誘發因素。老年人口的成長，尤其是在已開發地區，正顯著加速市場成長，因為與老齡化相關的脂質代謝變化會增加血脂異常症的風險。
藥物研發領域的技術進步，包括PCSK9抑制劑和聯合治療的出現，徹底改變了治療模式，為難治性高高膽固醇症患者拓展了治療選擇。不斷上漲的醫療成本、日益提高的診斷能力以及人們對心血管疾病預防保健意識的增強，正推動市場進一步擴張。然而，該市場也面臨著許多限制因素，例如，隨著重磅他汀類藥物專利到期，學名藥的競爭和價格下降；新藥認證的嚴格監管要求；以及人們對某些降脂藥物長期安全性的擔憂。
此外，高昂的治療費用，尤其是像PCSK9抑制劑這樣的新型治療方法，限制了價格敏感市場的可及性，並造成了報銷方面的挑戰。儘管有這些限制，發展中經濟體尚未開發的市場仍蘊藏著巨大的機遇，這些經濟體醫療基礎設施的改善和中產階級人口的成長正在推動需求。
個人化醫療、生物標記指導治療方法和新型藥物遞送方法的發展蘊藏著盈利的商機。此外，人們越來越關注聯合治療以實現最佳血脂靶點，以及治療罕見遺傳性血脂異常症的潛力，這些都為投資創新療法的製藥公司提供了顯著的成長前景。
本次調查的主要特點
- 本報告對全球血脂異常症治療市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和復合年成長率百分比。
- 我們將重點介紹各個細分市場的潛在商機，並說明該市場具有吸引力的投資提案矩陣。
- 該研究還提供了有關市場促進因素、阻礙因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本報告根據以下參數對全球血脂異常症治療市場的主要企業進行了分析：公司概況、產品系列、主要特徵、財務績效和策略。
- 本報告的研究結果將使負責人和經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 這份全球血脂異常症治療市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過分析全球血脂異常症治療市場所使用的各種策略矩陣輕鬆做出決策。
目錄
第1章 研究目標與前提條件
- 調查目的
- 先決條件
- 簡稱
第2章 市場範圍
- 報告概述
- 市場定義和範圍
- 執行摘要
第3章 市場動態、監理及趨勢分析
- 市場動態
- 促進要素
- 抑制因素
- 機會
- 影響分析
- 重大進展
- 法規環境
- 產品上市及核准
- PEST分析
- 波特分析
- 併購趨勢
- 產業趨勢
4. 2020-2032年全球血脂異常症治療市場（依適應症分類）
- 高膽固醇症
- 高三酸甘油脂血症
- 混合型血脂異常
- 動脈粥狀硬化性心血管疾病（ASCVD）
- 遺傳性脂蛋白脂肪酶缺乏症
- 其他（遺傳性轉甲狀腺素蛋白介導的類澱粉沉積症）
5. 2020-2032年全球血脂異常症治療市場（依藥物類別分類）
- 他汀類藥物
- PCSK9抑制劑
- 膽汁酸螯合劑
- 膽固醇吸收抑制劑
- 貝特類藥物
- 菸鹼酸（維生素B3）
- Omega-3脂肪酸
- 聯合治療
- 其他後期藥物
6. 2020-2032年全球血脂異常症藥物市場（依類型分類）
- 非專利的
- 品牌
7. 2020-2032年全球血脂異常症藥物市場（依給藥途徑分類）
- 口服
- 腸外
8. 2020-2032年全球血脂異常症治療市場（依年齡層分類）
- 成人
- 兒童
- 老年人
9. 2020-2032年全球血脂異常症治療市場（依性別分類）
- 男性
- 女士
10. 2020-2032年全球血脂異常症治療市場（依通路分類）
- 零售藥房
- 網路藥房
- 醫院藥房
第11章 2020-2032年全球血脂異常症治療市場（按地區分類）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第12章 競爭格局
- Amgen
- Sanofi
- Regeneron Pharmaceuticals
- Novartis
- Merck &Co.
- Pfizer
- AstraZeneca
- Daiichi Sankyo
- Kowa Pharmaceuticals America
- Esperion Therapeutics
- Amarin Corporation
- Chiesi Global Rare Diseases
- AbbVie
- Viatris
- Teva Pharmaceutical Industries
第13章 分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map
第14章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Lipid Disorder Treatment Market is estimated to be valued at USD 30.14 Bn in 2025 and is expected to reach USD 51.32 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 30.14 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.90% | 2032 Value Projection: | USD 51.32 Bn |
The global lipid disorder treatment market represents a critical segment within the pharmaceutical and healthcare industry, addressing the growing prevalence of dyslipidemia and associated cardiovascular complications worldwide. Lipid disorders, characterized by abnormal levels of cholesterol, triglycerides, and other lipoproteins in the blood, have emerged as a significant public health concern affecting millions of individuals globally.
Conditions, including hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia, are primary risk factors for cardiovascular diseases, which remain the leading cause of mortality worldwide. The treatment landscape encompasses various therapeutic approaches, including statins, fibrates, bile acid sequestrants, PCSK9 inhibitors, and emerging novel therapies that target different pathways in lipid metabolism.
The market is driven by increasing awareness of cardiovascular health, rising prevalence of obesity and diabetes, sedentary lifestyles, and aging populations across developed and developing nations. Additionally, continuous research and development activities have led to the introduction of innovative treatment modalities with improved efficacy and safety profiles, contributing to market expansion and providing healthcare professionals with diverse therapeutic options to manage lipid disorders effectively.
Market Dynamics
The global lipid disorder treatment market is primarily driven by the escalating prevalence of cardiovascular diseases and metabolic disorders, with obesity, diabetes, and hypertension serving as key contributing factors to dyslipidemia worldwide. The growing geriatric population, particularly in developed regions, significantly amplifies market growth as age-related lipid metabolism changes increase susceptibility to lipid disorders.
Technological advancements in drug development, including the emergence of PCSK9 inhibitors and combination therapies, have revolutionized treatment paradigms and expanded therapeutic options for patients with refractory hypercholesterolemia. Increasing healthcare expenditure, improved diagnostic capabilities, and rising awareness about preventive cardiovascular care further propel market expansion. However, the market faces substantial restraints including patent expirations of blockbuster statin drugs leading to generic competition and price erosion, stringent regulatory requirements for new drug approvals, and concerns regarding long-term safety profiles of certain lipid-lowering medications.
Additionally, high treatment costs, particularly for novel therapies like PCSK9 inhibitors, limit accessibility in price-sensitive markets and create reimbursement challenges. Despite these constraints, significant opportunities emerge from untapped markets in developing economies where healthcare infrastructure improvements and growing middle-class populations drive demand.
The development of personalized medicine approaches, biomarker-guided therapies, and novel drug delivery systems present lucrative opportunities. Furthermore, increasing focus on combination therapies to achieve optimal lipid targets and the potential for treating rare genetic lipid disorders offer substantial growth prospects for pharmaceutical companies investing in innovative therapeutic solutions.
Key Features of the Study
- This report provides in-depth analysis of the global lipid disorder treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global lipid disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Amgen, Sanofi, Regeneron Pharmaceuticals, Novartis, Merck and Co., Pfizer, AstraZeneca, Daiichi Sankyo, Kowa Pharmaceuticals America, Esperion Therapeutics, Amarin Corporation, Chiesi Global Rare Diseases, AbbVie, Viatris, and Teva Pharmaceutical Industries
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global lipid disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lipid disorder treatment market
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Hypercholesterolemia
- Primary Hypercholesterolemia
- Familial Hypercholesterolemia
- Hypertriglyceridemia
- Mixed Dyslipidemia
- Elevated LDL-C and Triglycerides
- Low HDL-C with Elevated LDL-C
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Familial Lipoprotein Lipase Deficiency
- Others (Hereditary Transthyretin-Mediated Amyloidosis)
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Statins
- Atorvastatin
- Rosuvastatin
- Simvastatin
- Others (Pravastatin, etc.)
- PCSK9 Inhibitors
- Alirocumab
- Evolocumab
- Others (Inclisiran, etc.)
- Bile Acid Sequestrants
- Colesevelam
- Colestipol
- Others (Cholestyramine, etc.)
- Cholesterol Absorption Inhibitors
- Ezetimibe
- Bempedoic Acid
- Fibrates
- Fenofibrate
- Gemfibrozil
- Niacin (Vitamin B3)
- Nicotinic Acid
- Omega-3 Fatty Acids
- Icosapent ethyl (Vascepa)
- Omega-3-acid ethyl esters (Lovaza)
- Combination Therapies
- Ezetimibe/Statin Combinations
- Other Late Phase Drugs
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Generic
- Brand
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adults
- Pediatric
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Amgen
- Sanofi
- Regeneron Pharmaceuticals
- Novartis
- Merck & Co.
- Pfizer
- AstraZeneca
- Daiichi Sankyo
- Kowa Pharmaceuticals America
- Esperion Therapeutics
- Amarin Corporation
- Chiesi Global Rare Diseases
- AbbVie
- Viatris
- Teva Pharmaceutical Industries
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Lipid Disorder Treatment Market, By Indication
- Global Lipid Disorder Treatment Market, By Drug Class
- Global Lipid Disorder Treatment Market, By Type
- Global Lipid Disorder Treatment Market, By Route of Administration
- Global Lipid Disorder Treatment Market, By Age Group
- Global Lipid Disorder Treatment Market, By Gender
- Global Lipid Disorder Treatment Market, By Distribution Channel
- Global Lipid Disorder Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Lipid Disorder Treatment Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hypercholesterolemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Primary Hypercholesterolemia
- Familial Hypercholesterolemia
- Hypertriglyceridemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mixed Dyslipidemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Elevated LDL-C and Triglycerides
- Low HDL-C with Elevated LDL-C
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Familial Lipoprotein Lipase Deficiency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Hereditary Transthyretin-Mediated Amyloidosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Lipid Disorder Treatment Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Atorvastatin
- Rosuvastatin
- Simvastatin
- Others (Pravastatin, etc.)
- PCSK9 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alirocumab
- Evolocumab
- Others (Inclisiran, etc.)
- Bile Acid Sequestrants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Colesevelam
- Colestipol
- Others (Cholestyramine, etc.)
- Cholesterol Absorption Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ezetimibe
- Bempedoic Acid
- Fibrates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Fenofibrate
- Gemfibrozil
- Niacin (Vitamin B3)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nicotinic Acid
- Omega-3 Fatty Acids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Icosapent ethyl (Vascepa)
- Omega-3-acid ethyl esters (Lovaza)
- Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ezetimibe/Statin Combinations
- Other Late Phase Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Lipid Disorder Treatment Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Lipid Disorder Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Lipid Disorder Treatment Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Lipid Disorder Treatment Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Lipid Disorder Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Lipid Disorder Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kowa Pharmaceuticals America
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Esperion Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amarin Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chiesi Global Rare Diseases
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
